ClinicalTrials.gg
Active, not recruitingNCT05642780Updated Oct 14, 2025

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

A Phase 2 interventional study of SKB264 and Pembrolizumab in Solid Tumor, sponsored by Klus Pharma Inc.. Active, not recruiting at 48 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by Klus Pharma Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer,advanced endometrial cancer.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Klus Pharma Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with (ECOG) performance status score of 0 or 1 .
  2. Subjects with expected survival ≥ 3 months.
  3. Cohort A: Subjects with recurrent or cervical cancer
  4. Cohort B: Subjects with locally advanced or metastatic urothelial carcinoma
  5. Cohort C: Subjects with recurrent ovarian cancer
  6. Cohort D: Subjects with metastatic prostate cancer
  7. Subjects have at least one per (RECIST) 1.1 criteria.
  8. Subjects able to provide tumor blocks or slides for biomarker test.
  9. Subjects have relatively good organ function and bone marrow function.
  10. Subjects must have recovered from all toxicities from previous therapy with the exception of toxicities not considered a safety risk.
  11. use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  12. Subject is capable of giving signed .
  13. Cohort E: Subjects with advanced endometrial cancer.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with active or untreated central nervous system (CNS) and/or carcinomatous meningitis are not eligible.
  2. Subjects who suffer from cardiovascular diseases of clinical significance.
  3. Subjects with serious and/or uncontrolled concomitant diseases.
  4. Subjects diagnosed active or .
  5. Subjects have known (HIV) infection that is not well controlled.
  6. Subjects with known active tuberculosis.
  7. Known allergy or to pembrolizumab or SKB264, or the of pembrolizumab or SKB264.
  8. Subjects with history of allogeneic tissue/solid organ transplant.
  9. Subjects previously treated with TROP2 targeted therapy.
  10. Subjects who are vaccinated with within 30 days before the first dose, or plan to be vaccinated with live vaccine during the study period.
  11. Subjects participating in another clinical study, unless it is an observational (non-intervention) clinical study or the follow-up period of an intervention study.
  12. The Investigator considers other situations that will interfere with the evaluation of the study intervention or the safety of the subjects or the interpretation of the results of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    cohort A

    subjects will receive SKB264 in combination with pembrolizumab by intravenous administration

    Drug: SKB264 · Drug: Pembrolizumab

  • Experimental
    cohort B

    subjects will receive SKB264 in combination with pembrolizumab by intravenous administration

    Drug: SKB264 · Drug: Pembrolizumab

  • Experimental
    cohort C

    subjects will receive SKB264 in combination with pembrolizumab by intravenous administration

    Drug: SKB264 · Drug: Pembrolizumab

  • Experimental
    cohort D

    subjects will receive SKB264 in combination with pembrolizumab by intravenous administration

    Drug: SKB264 · Drug: Pembrolizumab

  • Experimental
    Cohort E

    subjects will receive SKB264 in combination with pembrolizumab by intravenous administration

    Drug: SKB264 · Drug: Pembrolizumab

Interventions

  • DrugSKB264

    be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;

  • be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;

    Also known as: Keytruda

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT) and adverse events (AEs)

    Incidence and severity of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: From subject sign the ICF to 30 days after the last dose of study treatment

  2. Objective Response Rate (ORR)

    ORR is defined as the proportion of subjects with confirmed CR or PR as the best overall response assessed per RECIST 1.1.

    Time frame: From baseline until disease progression, death or other protocol defined reason up to approximately 21 months

  3. Prostate-specific antigen (PSA) response rate (Cohort D)

    The percentage of subjects in the analysis population who have a negative change (decrease) in PSA level of ≥ 50% measured twice ≥ 3 weeks apart

    Time frame: From baseline until disease progression, death or other protocol defined reason up to approximately 21 months

07

Study locations

48 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Nov 2027, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 8, 2022
StartActual
Jan 17, 2023
Primary completionEst.
Nov 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05642780
Lead sponsor
Klus Pharma Inc.
Collaborators
Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc., Clario
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Jan 17, 2023
Primary completion
Nov 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab tirumotecan

Start the discussion